UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

Leukemia, 2013-10, Vol.27 (10), p.2016-2022

2013

Volltextzugriff (PDF)

P692: IMMUNE FACTORS MAINTAINING TREATMENT‐FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB

HemaSphere, 2022-06, Vol.6, p.587-588

2022

Volltextzugriff (PDF)

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

Bone marrow transplantation (Basingstoke), 2006-08, Vol.38 (4), p.319-320

2006

Volltextzugriff (PDF)

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2005-09, Vol.36 (5), p.417-424

2005

Volltextzugriff (PDF)

Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (15_suppl), p.e19039-e19039

2021

Volltextzugriff (PDF)

Imatinib‐associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Clinical and laboratory haematology, 2006-06, Vol.28 (3), p.208-210

2006

Volltextzugriff (PDF)

Improved Transfusion Independence Rates for Momelotinib versus Ruxolitinib in Anaemic Jaki Naive Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status

BRITISH JOURNAL OF HAEMATOLOGY, 2022, Vol.197, p.81

2022

Volltextzugriff (PDF)

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571

Clinical and laboratory haematology, 2003-10, Vol.25 (5), p.293-296

2003

Volltextzugriff (PDF)

Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naive Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, Vol.21, p.S353

2021

Volltextzugriff (PDF)

Quality of life in CML patients after HCT pretreated with second generation tyrosine kinase inhibitors

Acta haematologica polonica, 2015-09, Vol.46, p.193-194

2015

Volltextzugriff (PDF)

Wczesne i późne wyniki transplantacji allogenicznych komórek krwiotwórczych u pacjentów z przewlekłą białaczką szpikową leczonych inhibitorami kinaz drugiej generacji

Acta haematologica polonica, 2013-07, Vol.44, p.161-162

2013

Volltextzugriff (PDF)

Leczenie inhibitorami kinazy tyrozynowej drugiej generacji u pacjentów z przewlekłą białaczką szpikową może zmniejszyć ryzyko występowania choroby przeszczep-przeciwko-gospodarzowi po allotransplantacji komórek krwiotwórczych

Acta haematologica polonica, 2015-09, Vol.46, p.38-39

2015

Volltextzugriff (PDF)

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

Hematology (Luxembourg), 2009-08, Vol.14 (4), p.227-236

2009

Volltextzugriff (PDF)

CASE REPORT: Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Clinical and laboratory haematology, 2006-06, Vol.28 (3), p.208-210

2006

Volltextzugriff (PDF)

Transplantation of hemopoietic stem cells in treatment of chronic myeloid leukemia

Polskie archiwum medycyny wewne̦trznej, 2001, Vol.105 Suppl, p.395

2001

Volltextzugriff (PDF)

Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome

American journal of hematology, 2003-08, Vol.73 (4), p.249-255

2003

Volltextzugriff (PDF)

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571: Modification of the clonogenic capacity of bone marrow cells

Clinical and laboratory haematology, 2003-10, Vol.25 (5), p.293-296

2003

Volltextzugriff (PDF)

Large granular lymphocytic leukemia

Wiadomości lekarskie (1960), 1998, Vol.51 (7-8), p.368

1998

Volltextzugriff (PDF)

Evaluation of treatment outcome in patients with idiopathic thrombocytopenia in the years 1980-1982

Wiadomości lekarskie (1960), 1993-12, Vol.46 (23-24), p.902

1993

Volltextzugriff (PDF)

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

Bone marrow transplantation, 2006, Vol.38 (4), p.319-320

2006

Volltextzugriff (PDF)

Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Clinical & Laboratory Haematology, 2006, Vol.28 (3), p.208-210

2006

Volltextzugriff (PDF)

Evaluation of bone marrow grafts and hemopoietic chimerism using PCR hypervariable sequencing with variable number tandem repeat sequences

Polski tygodnik lekarski (Warsaw, Poland : 1960), 1995-09, Vol.50 (36-39), p.73

1995

Volltextzugriff (PDF)

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.141-141

2021

Volltextzugriff (PDF)

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-09, Vol.10 (9), p.2367-2374.e3

2022

Volltextzugriff (PDF)

Stereochemistry of alkyl 3-substituted 4-halotetrahydro-2-oxo-3-furancarboxylates: 2-1H and 13C NMR spectra

Organic Magnetic Resonance, 1983-03, Vol.21 (3), p.157-162

1983

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Sprache

Englisch
(21)
Polnisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

P692: IMMUNE FACTORS MAINTAINING TREATMENT‐FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

Imatinib‐associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Improved Transfusion Independence Rates for Momelotinib versus Ruxolitinib in Anaemic Jaki Naive Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571

Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naive Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status

Quality of life in CML patients after HCT pretreated with second generation tyrosine kinase inhibitors

Wczesne i późne wyniki transplantacji allogenicznych komórek krwiotwórczych u pacjentów z przewlekłą białaczką szpikową leczonych inhibitorami kinaz drugiej generacji

Leczenie inhibitorami kinazy tyrozynowej drugiej generacji u pacjentów z przewlekłą białaczką szpikową może zmniejszyć ryzyko występowania choroby przeszczep-przeciwko-gospodarzowi po allotransplantacji komórek krwiotwórczych

Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

CASE REPORT: Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Transplantation of hemopoietic stem cells in treatment of chronic myeloid leukemia

Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome

Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571: Modification of the clonogenic capacity of bone marrow cells

Large granular lymphocytic leukemia

Evaluation of treatment outcome in patients with idiopathic thrombocytopenia in the years 1980-1982

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia

Evaluation of bone marrow grafts and hemopoietic chimerism using PCR hypervariable sequencing with variable number tandem repeat sequences

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

Stereochemistry of alkyl 3-substituted 4-halotetrahydro-2-oxo-3-furancarboxylates: 2-1H and 13C NMR spectra

Suchergebnisse filtern